Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bahij Khuri

Interventional Cardiology Baton Rouge, LA Medical Doctor

NPI 1144253717 CMS profile 279116

9001 Summa Ave, Baton Rouge, LA 70809

Open in the dashboard

General payments

$4,989

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bahij Khuri of Baton Rouge, LA is reported in the CMS Open Payments database as having received $4,989 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,183 31
2024 General $841 20
2023 General $1,631 26
2022 General $658 16
2021 General $110 7
2020 General $268 6
2019 General $298 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bahij Khuri
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Bahij Khuri were reported at $1,183. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Bahij Khuri Interventional Cardiology median Middle half National median
2019 $298 $1,097 $329–$3,048 $163
2020 $268 $473 $161–$1,480 $114
2021 $110 $677 $233–$1,827 $132
2022 $658 $978 $333–$2,724 $149
2023 $1,631 $1,136 $382–$2,986 $160
2024 $841 $1,181 $395–$3,326 $164
2025 $1,183 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $955 12 payments
  2. Abiomed $730 12 payments
  3. Siemens Medical Solutions USA, Inc. $653 3 payments
  4. Kestra Medical Technology Services, Inc. $502 15 payments
  5. Cardiovascular Systems Inc. $366 6 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $321 15 payments
  7. Boston Scientific Corporation $281 9 payments
  8. Abbott Laboratories $230 8 payments
  9. Medtronic, Inc. $183 5 payments
  10. Philips Electronics North America Corporation $129 4 payments
  11. Other $639 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,364 115 payments
  2. Travel and Lodging $605 2 payments
  3. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $690 8 payments
  2. Impella $405 6 payments
  3. Assure WCD Cardiology/Vascular Diseases $356 13 payments
  4. LifeVest $321 15 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $236 2 payments
  6. Assure WCD Cardiology $146 2 payments
  7. Peripheral Orbital Atherectomy System $133 2 payments
  8. Diamondback Coronary $132 3 payments
  9. Barostim Neo System $114 2 payments
  10. Diamondback Peripheral $113 2 payments
  11. Other $1,300 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

8,000

Median for Interventional Cardiology: 2,236

Drug cost

$1,100,056

Median for Interventional Cardiology: $380,412

Branded share of claims

33.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 508 $428,165
Repatha Sureclick Evolocumab Brand 313 $208,017
Xarelto Rivaroxaban Brand 95 $102,742
Entresto Sacubitril/Valsartan Brand 81 $70,787
Brilinta Ticagrelor Brand 86 $44,389
Vascepa Icosapent Ethyl Brand 66 $37,891
Praluent Pen Alirocumab Brand 46 $37,492
Jardiance Empagliflozin Brand 28 $23,268
Ranolazine Er Ranolazine Brand 327 $22,633
Wegovy Semaglutide Brand 15 $22,046

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$91,166

Medicare's payments for the services billed

Medicare patients

1,166

Average age 74

Services billed

2,208

646 women, 520 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 47%
Diabetes 43%
Chronic kidney disease 42%
Heart failure 34%
Atrial fibrillation 27%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FUROSCIX
  • SCPHARMACEUTICALS INC. $24
$24 — —
ABILIFY
  • E.R. Squibb & Sons, L.L.C. $20
$20 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $17
$17 — —
RYBELSUS
  • Novo Nordisk Inc $9
$9 — —
Ozempic
  • Novo Nordisk Inc $9
$9 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record